<DOC>
	<DOCNO>NCT00619957</DOCNO>
	<brief_summary>Two year study determine safety efficacy weekly 35 mg Risedronate dose men osteoporosis follow two year follow-up study .</brief_summary>
	<brief_title>Efficacy Safety Risedronate Therapy Administered 35 mg Once A Week Men With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Documented osteoporosis femoral neck lumbar spine BMI great equal 35</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>